Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$641.14K$641.14K−16.9% vs Q2 2018 Net Income-$10.24M-$10.24MN/M vs Q2 2018 EPS Diluted-$0.98-$0.98N/M vs Q2 2018 Operating Income-$7,705,637N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,309,555N/M Margins · derivedOperating margin-1201.9%−316.9 pt vs Q2 2018
Net margin-1597.9%−621.1 pt vs Q2 2018
ended Mar 31, 2019 · filed May 15, 2019 · 45 d after period end